ADC Therapeutics Enters Material Definitive Agreement on Jan 18

TL;DR

**ADC Therapeutics just signed a big deal; details pending but it's a game-changer.**

AI Summary

ADC Therapeutics SA filed an 8-K on January 24, 2024, reporting a material definitive agreement entered into on January 18, 2024. This filing indicates a significant corporate action, likely a new contract or partnership, which could impact the company's financial outlook and strategic direction. Investors should pay close attention to the details of this agreement as it could signal future revenue streams or operational changes for the pharmaceutical company.

Why It Matters

This filing signals a new, important agreement for ADC Therapeutics, which could significantly alter its business operations, financial performance, or strategic partnerships. Understanding the nature of this agreement is crucial for assessing the company's future prospects.

Risk Assessment

Risk Level: medium — The filing indicates a 'material definitive agreement' but lacks specific details, creating uncertainty about its financial impact and implications for the company.

Analyst Insight

Investors should monitor ADC Therapeutics' subsequent filings and press releases for specific details regarding the 'Material Definitive Agreement' to understand its potential impact on the company's financials and strategic direction. Without further information, it's difficult to assess the full implications.

Key Numbers

• 001-39071 — Commission File Number (identifies ADC Therapeutics' filings with the SEC)
• 20240118 — Conformed Period of Report (indicates the date of the event being reported)
• 20240124 — Filed As Of Date (the date the 8-K was officially filed)
• CHF 0.08 — Par Value per Share (the nominal value of each common share)

Key Players & Entities

• ADC Therapeutics SA (company) — the registrant filing the 8-K
• January 18, 2024 (date) — date of the earliest event reported (entry into material definitive agreement)
• January 24, 2024 (date) — date the 8-K was filed
• CHF 0.08 (dollar_amount) — par value per common share
• New York Stock Exchange (company) — exchange where ADC Therapeutics' common shares are registered

Forward-Looking Statements

• ADC Therapeutics will provide more details about the 'Material Definitive Agreement' in a subsequent filing or press release. (ADC Therapeutics SA) — high confidence, target: 2024-03-31
• The 'Material Definitive Agreement' will involve a partnership or licensing deal related to a pharmaceutical product. (ADC Therapeutics SA) — medium confidence, target: 2024-06-30

FAQ

Filing Documents

• dp205528_8k.htm (8-K) — 26KB
• dp205528_ex1001.htm (EX-10.1) — 38KB
• 0000950103-24-001047.txt ( ) — 242KB
• adct-20240118.xsd (EX-101.SCH) — 3KB
• adct-20240118_lab.xml (EX-101.LAB) — 33KB
• adct-20240118_pre.xml (EX-101.PRE) — 22KB
• dp205528_8k_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On January 18, 2024, ADC Therapeutics SA (the "Company") entered into an agreement (the "Redmile Agreement") with the Redmile Group, LLC ("Redmile") regarding preemptive rights and advance subscription rights with respect to shares of the Company. The Company agreed that the Company's board of directors will not restrict the preemptive rights of Redmile or its affiliates based on Article 4a(4)(g) of the Company's articles of association or restrict the advance subscription rights of Redmile or its affiliates based on Article 4c(3) of the Company's articles of association as long as (i) Redmile (including its affiliates and any other person or entity forming a "group" (as defined in Rule 13d-5 under the Exchange Act)) does not directly or indirectly control, own or have the right to control or own, collectively, shares representing more than 20% of the Company's share capital or (ii) Redmile (including its affiliates and any other person or entity forming a "group" (as defined in Rule 13d-5 under the Exchange Act)) directly or indirectly controls, owns or has the right to control or own, collectively, shares representing more than 20% of the Company's share capital but the Company's board of directors determines that Redmile does not have an intent to effect a change of control of the Company. If, at any time, Redmile (including its affiliates and any other person or entity forming a "group" (as defined in Rule 13d-5 under the Exchange Act)) directly or indirectly controls, owns or has the right to control or own, collectively, shares representing more than 20% of the Company's share capital and the Company's board of directors determines that Redmile has an intent to effect a change of control of the Company, the Company's board of directors will provide a reasonable opportunity to Redmile to explain its intentions. Thereafter, if the Company's board of directors determines that Redmile does not intend to effe

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Letter Agreement, dated January 18, 2024, between ADC Therapeutics SA and Redmile LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADC Therapeutics SA Date: January 24, 2024 By: /s/ Peter J. Graham Name: Peter J. Graham Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR